

**The 4th^d International
Drug Discovery and Development
Forum 2018**

**NEW TRENDS IN DRUG DISCOVERY:
Small-Molecule Approaches to
Immunotherapy and Drug Conjugates**

October 22-24, 2018

The New Centre for Translational Biology

RI-MUHC, Glen site

Presented by:

**The McGill-CIHR
Drug Development
Training Program**

*Educational Sessions
in collaboration with the advanced technological platforms of the Centre for
Translational Biology, the Research Institute of the MUHC*

DAY 1 - MONDAY, OCTOBER 22, 2018

TIME	Special Training Session	ROOM
9:00-10:30	 Dr. Min Fu Advanced Microscopy for Drug Discovery	E01.5135
10:45-12:00	 Dr. Robert Hambalek Introduction to Hyphenated NMR Techniques: Biochemical / Biomedical Applications	ES1.1129 Auditorium
1:00-2:00	 Dr. Jeff Xia Metabolomics – From Basic Concepts to Practical Data Analysis	ES1.1129 Auditorium
2:00-3:00	 Dr. Kurt Dejgaard Practical Proteomics	ES1.1129 Auditorium
3:00-4:00	 Dr. Nidia Lauzon Recent Applications of MALDI-TOF Mass Spectrometry and Imaging Mass Spectrometry	E01.5135

DAY 2 - TUESDAY, OCTOBER 23, 2018

8:30 - 9:00	AUDITORIUM ES1.1129	Registration Coffee
9:00– 9:15		Dr. Ciriaco Picciorello Director of Centre of Excellence in Translational Immunology <i>Opening statement</i>
SYMPOSIUM I SMALL MOLECULES IMMUNO-MODULATORS		
9:15-10:00		Dr. Joshua E. Allen Senior Vice President, Research & Development Oncoceutics Inc. University City Science Center Philadelphia, PA USA <i>Phenotypic discovery of the first DRD2-targeting agent for clinical oncology</i>
10:00-10:45		Dr. Hang Hubert Yin School of Pharmaceutical Sciences Tsinghua University, Beijing China <i>Small Molecule Immunomodulators that Target Toll- Like Receptors</i>
10:45-11:00 COFFEE BREAK		

11:00-12:00		<p>Dr. Paul J. Davis Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, N.Y. USA</p> <p><i>The Thyroid Hormone Receptor on the Cancer Cell Plasma Membrane Integrin $\alpha\beta 3$ Regulates Cell Proliferation, Anti-Apoptosis, Immune Checkpoint Defense and Angiogenesis</i></p>
12:00 – 1:00 LUNCH BREAK		
SYMPOSIUM II – ANTIBODY DRUG CONJUGATES		
1:00-1:45		<p>Dr. Aditya Bardia Massachusetts General Hospital Cancer Center Harvard Medical School, USA</p> <p><i>Antibody Drug Conjugates for Treatment of Breast Cancer: The Next Generation of Targeted Chemotherapeutics</i></p>
1:45-2:30		<p>Dr. David M. Perrin University of British Columbia, Canada Vancouver Campus</p> <p><i>From new F18-PET imaging agents to targeted toxins for therapy.</i></p>
2:30 – 2:45 COFFEE BREAK		
2:45-3:30		<p>Dr. Maria Luz Jaramillo, National Research Council of Canada Montreal, Quebec</p> <p><i>Antibody and ADC Development at the National Research Council</i></p>

3:30-4:15		<p>Dr. Jeff Leyton Department of Nuclear Medicine and Radiobiology Faculty of Medicine and Health Sciences Université de Sherbrooke, Quebec</p> <p><i>ADCs with integrated endosome escape and nuclear-directional intracellular trafficking-control capabilities: An approach for next-generation cancer therapeutics</i></p>
DAY 3 - WEDNESDAY, OCTOBER 24, 2018		
9:00 - 9:30	AUDITORIUM ES1.1129	Registration Coffee
9:30- 9:45		<p><i>Welcome speech</i> Dr. Bertrand J. Jean-Claude DDTP and Drug Discovery Platform Director</p>
9:45-10:30		<p>KEYNOTE SPEAKER Dr. Wayne Guida Professor & Chair of the Chemistry Dept. University of South Florida Tampa, Florida, USA TITLE: TBA</p>
10:30-12:00		Oral presentations by trainees <i>(Performance Prizes to be presented at the Award Ceremony)</i>
12:00 – 1:00 LUNCH BREAK		
1:00-2:30	BLOC E - ATRIUM	Poster Session & Commercial Exhibition
2:30 – 4:00	BLOC E Auditorium	Cocktail Award Ceremony

A special thanks to our proud corporate sponsors



McGill University
Health Centre

